BR112016008871A8 - sonda de imageamento tau, seu método de produção composição farmacêutica, kit, uso, métodos de separação de compostos racêmico - Google Patents

sonda de imageamento tau, seu método de produção composição farmacêutica, kit, uso, métodos de separação de compostos racêmico Download PDF

Info

Publication number
BR112016008871A8
BR112016008871A8 BR112016008871A BR112016008871A BR112016008871A8 BR 112016008871 A8 BR112016008871 A8 BR 112016008871A8 BR 112016008871 A BR112016008871 A BR 112016008871A BR 112016008871 A BR112016008871 A BR 112016008871A BR 112016008871 A8 BR112016008871 A8 BR 112016008871A8
Authority
BR
Brazil
Prior art keywords
kit
separation
methods
pharmaceutical composition
production method
Prior art date
Application number
BR112016008871A
Other languages
English (en)
Inventor
Okamura Nobuyuki
FURUMOTO Shozo
Kudo Yukitsuka
Original Assignee
Clino Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clino Ltd filed Critical Clino Ltd
Publication of BR112016008871A8 publication Critical patent/BR112016008871A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B57/00—Separation of optically-active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Abstract

é fornecido um composto representado pela fórmula (i) com a qual é possível realizar o imageamento tau com uma alta especificidade para tau, e com excelente sensibilidade, ao mesmo tempo caracterizado pelo fato de que tendo alta captação cerebral, baixas ou não existentes propriedades de busca óssea, e baixa ou inexistente toxicidade, e representado pela fórmula (i).
BR112016008871A 2013-10-22 2014-10-22 sonda de imageamento tau, seu método de produção composição farmacêutica, kit, uso, métodos de separação de compostos racêmico BR112016008871A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013233470 2013-10-22
PCT/JP2014/078146 WO2015060365A1 (ja) 2013-10-22 2014-10-22 タウイメージングプローブ

Publications (1)

Publication Number Publication Date
BR112016008871A8 true BR112016008871A8 (pt) 2020-03-24

Family

ID=52992954

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008871A BR112016008871A8 (pt) 2013-10-22 2014-10-22 sonda de imageamento tau, seu método de produção composição farmacêutica, kit, uso, métodos de separação de compostos racêmico

Country Status (13)

Country Link
US (1) US20160244411A1 (pt)
EP (1) EP3061748A4 (pt)
JP (1) JPWO2015060365A1 (pt)
KR (1) KR20160072226A (pt)
CN (1) CN105814023A (pt)
AU (1) AU2014338155B2 (pt)
BR (1) BR112016008871A8 (pt)
CA (1) CA2928313A1 (pt)
IL (1) IL245221A0 (pt)
MX (1) MX2016005233A (pt)
RU (1) RU2016119524A (pt)
SG (2) SG11201603131RA (pt)
WO (1) WO2015060365A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522414D0 (en) * 2015-12-18 2016-02-03 Clino Ltd Monoamine oxidase B binders
JP6946412B2 (ja) * 2016-07-18 2021-10-06 ヤンセン ファーマシューティカ エヌ．ベー． タウｐｅｔ画像化リガンド
WO2019014429A1 (en) * 2017-07-12 2019-01-17 Dana-Farber Cancer Institute, Inc. COMPOUNDS FOR THE DEGRADATION OF TAU PROTEIN
CN107488144B (zh) * 2017-08-09 2021-06-04 复旦大学 一种可以特异性结合并能抑制Tau蛋白聚集的分子及其制备方法和应用
JP7284490B2 (ja) 2018-08-07 2023-05-31 国立大学法人東北大学 モノアミンオキシダーゼｂイメージングプローブ
KR102369838B1 (ko) * 2020-04-16 2022-03-04 연세대학교 산학협력단 퀴놀린 유도체를 유효성분으로 포함하는 성상교세포증 관련 질환의 병변 경계부 검출용 조영제 조성물
KR20210128125A (ko) * 2020-04-16 2021-10-26 연세대학교 산학협력단 퀴놀린 유도체를 유효성분으로 포함하는 퇴행성 뇌질환에 의한 치매의 병변 경계부 검출용 조영제 조성물
CN111892534A (zh) * 2020-08-04 2020-11-06 中国科学技术大学 一种pH敏感的荧光探针、其制备方法及其应用
CN113754583A (zh) * 2021-09-03 2021-12-07 湖南工程学院 2-([2，2′-联喹啉基]-3-醚基)-1-乙醇及其衍生物及合成方法
CN113999172A (zh) * 2021-11-17 2022-02-01 湖南工程学院 2-((2-苯基喹啉-3-基)醚基)-1-乙醇及其衍生物及合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1574500A1 (en) 2002-12-16 2005-09-14 BF Research Institute, Inc. Quinoline derivative as diagnostic probe for disease with tau protein accumulation
US8691187B2 (en) * 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
US8483197B2 (en) * 2009-03-23 2013-07-09 Qualcomm Incorporated AP to legacy station SDMA protocol
US8491869B2 (en) 2009-03-23 2013-07-23 Eli Lilly And Company Imaging agents for detecting neurological disorders
KR101101977B1 (ko) 2009-04-09 2012-01-02 (주)에스메디 2-아릴나프탈렌, 2-아릴퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
JP5928901B2 (ja) * 2010-10-29 2016-06-01 クリノ株式会社 タウイメージングプローブ
US9040021B2 (en) * 2010-11-16 2015-05-26 Ge Healthcare Limited Heterocyclic compounds as imaging probes of tau pathology
GB201411571D0 (en) * 2014-06-30 2014-08-13 Ge Healthcare Ltd Radiolabelling method

Also Published As

Publication number Publication date
WO2015060365A1 (ja) 2015-04-30
CA2928313A1 (en) 2015-04-30
US20160244411A1 (en) 2016-08-25
JPWO2015060365A1 (ja) 2017-03-09
CN105814023A (zh) 2016-07-27
AU2014338155A1 (en) 2016-05-19
RU2016119524A (ru) 2017-11-28
EP3061748A1 (en) 2016-08-31
KR20160072226A (ko) 2016-06-22
SG11201603131RA (en) 2016-05-30
RU2016119524A3 (pt) 2018-06-14
SG10201803294PA (en) 2018-06-28
AU2014338155B2 (en) 2018-08-23
IL245221A0 (en) 2016-06-30
EP3061748A4 (en) 2017-04-05
MX2016005233A (es) 2017-01-05

Similar Documents

Publication Publication Date Title
BR112016008871A8 (pt) sonda de imageamento tau, seu método de produção composição farmacêutica, kit, uso, métodos de separação de compostos racêmico
CL2019003154A1 (es) Proceso de preparación de un compuesto intermediario de fórmula (vi) para la preparación de compuestos de cannabidiol. (divisional solicitud 201800079)
EA201791692A1 (ru) 4H-ПИРРОЛО[3,2-c]ПИРИДИН-4-ОНОВЫЕ ПРОИЗВОДНЫЕ
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
BR112016028288A2 (pt) ?composto, composição farmacêutica, métodos para tratamento de um indivíduo com uma doença ou condição e para inibir a quinase, e, uso de um composto?
CL2018000829A1 (es) Anticuerpos anti-cd19 humano con alta afinidad
BR112018012106A2 (pt) forma cristalina de inibidor de btk quinase e método de preparação da mesma
DOP2017000213A (es) Derivados de bencimidazol como inhibidores de bromodominio
DOP2015000245A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos
BR112016022785A8 (pt) composto, composição farmacêutica, kit farmacêutico para tratar um câncer, e, métodos de tratamento de uma doença e/ou uma condição e/ou um distúrbio e de síntese de um composto
CR20160171A (es) NUEVO OCTAHIDRO-CICLOBUTA[1,2-c; 3,4-c] DIPIRROL-2-ILO
AR094964A1 (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRASTORNOS RELACIONADOS CON LA FOSFOINOSITIDA 3-CINASA d (PI3Kd)
BR112017003421A2 (pt) formas sólidas cristalinas de 6-carbóxi-2-(3,5-diclorofenil)-benzoxazol
EA201890522A1 (ru) Способ получения противогрибковых соединений
CR20160135A (es) Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201990455A1 (ru) КОНДЕНСИРОВАННОЕ ТРИЦИКЛИЧЕСКОЕ ПРОИЗВОДНОЕ γ-АМИНОКИСЛОТЫ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И ЕГО МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
CR20120524A (es) Combinaciones que contienen 2,3-dihidroimidazo [1,2-c] quinazolina sustituida
BR112017000480A2 (pt) composição polimerizável, produto moldado, e uso dos mesmos
BR112017008794A2 (pt) inibidores de di-heteroaril histona desacetilase e seu uso em terapia
DOP2016000120A (es) Nuevos inhibidores de dgat2
EA201791671A1 (ru) 4-замещенные соединения бензоксаборола и их применение
CY1117414T1 (el) Παραγοντες αναστροφης αντιπηκτικου
MD3680243T2 (ro) Compus pentaciclic
CY1122423T1 (el) Παραγωγα πυριμιδινης χρησιμα ως εκλεκτικοι αναστολεις jak3 kai/ή jak1

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements